Sign in or Register   Sign in or Register
  |  

Mouse Anti-GPC1 Recombinant Antibody (CBLG1-1590) (CBMAB-G4500-LY)

This product is antibody recognizes GPC1. The antibody CBLG1-1590 immunoassay techniques such as: ELISA, IF, WB.
See all GPC1 antibodies

Summary

Host Animal
Mouse
Specificity
Human, Mouse
Clone
CBLG1-1590
Antibody Isotype
IgG1
Application
ELISA, IF, WB

Basic Information

Specificity
Human, Mouse
Antibody Isotype
IgG1
Clonality
Monoclonal
Application Notes
The COA includes recommended starting dilutions, optimal dilutions should be determined by the end user.

Formulations & Storage [For reference only, actual COA shall prevail!]

Format
Liquid
Purity
> 95% Purity determined by SDS-PAGE.
Storage
Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freezethaw cycles.

Target

Full Name
glypican 1
Introduction
Cell surface heparan sulfate proteoglycans are composed of a membrane-associated protein core substituted with a variable number of heparan sulfate chains. Members of the glypican-related integral membrane proteoglycan family (GRIPS) contain a core protein anchored to the cytoplasmic membrane via a glycosyl phosphatidylinositol linkage. These proteins may play a role in the control of cell division and growth regulation. [provided by RefSeq, Jul 2008]
Entrez Gene ID
Human2817
Mouse14733
UniProt ID
HumanP35052
MouseQ9QZF2
Function
Cell surface proteoglycan that bears heparan sulfate. Binds, via the heparan sulfate side chains, alpha-4 (V) collagen and participates in Schwann cell myelination (By similarity).

May act as a catalyst in increasing the rate of conversion of prion protein PRPN(C) to PRNP(Sc) via associating (via the heparan sulfate side chains) with both forms of PRPN, targeting them to lipid rafts and facilitating their interaction. Required for proper skeletal muscle differentiation by sequestering FGF2 in lipid rafts preventing its binding to receptors (FGFRs) and inhibiting the FGF-mediated signaling.
Biological Process
Cell migration Source: GO_Central
Heparan sulfate proteoglycan catabolic process Source: UniProtKB
Myelin assembly Source: UniProtKB
Negative regulation of fibroblast growth factor receptor signaling pathway Source: UniProtKB
Positive regulation of skeletal muscle cell differentiation Source: UniProtKB
Regulation of protein localization to membrane Source: GO_Central
Schwann cell differentiation Source: UniProtKB
Cellular Location
Cell membrane; Endosome. S-nitrosylated form recycled in endosomes. Localizes to CAV1-containing vesicles close to the cell surface. Cleavage of heparan sulfate side chains takes place mainly in late endosomes. Associates with both forms of PRNP in lipid rafts. Colocalizes with APP in perinuclear compartments and with CP in intracellular compartments. Associates with fibrillar APP amyloid-beta peptides in lipid rafts in Alzheimer disease brains.
Secreted glypican-1: Extracellular space
Involvement in disease
Associates (via the heparan sulfate side chains) with fibrillar APP amyloid-beta peptides in primitive and classic amyloid plaques and may be involved in the deposition of these senile plaques in the Alzheimer disease (AD) brain (PubMed:15084524).
Misprocessing of GPC1 is found in fibroblasts of patients with Niemann-Pick Type C1 disease. This is due to the defective deaminative degradation of heparan sulfate chains (PubMed:16645004).
PTM
S-nitrosylated in a Cu2+-dependent manner. Nitric acid (NO) is released from the nitrosylated cysteines by ascorbate or by some other reducing agent, in a Cu2+ or Zn2+ dependent manner. This free nitric oxide is then capable of cleaving the heparan sulfate side chains.
N- and O-glycosylated. N-glycosylation is mainly of the complex type containing sialic acid. O-glycosylated with heparan sulfate. The heparan sulfate chains can be cleaved either by the action of heparanase or, degraded by a deaminative process that uses nitric oxide (NO) released from the S-nitrosylated cysteines. This process is triggered by ascorbate, or by some other reducing agent, in a Cu2+- or Zn2+ dependent manner. Cu2+ ions are provided by ceruloproteins such as APP, PRNP or CP which associate with GCP1 in intracellular compartments or lipid rafts.
This cell-associated glypican is further processed to give rise to a medium-released species.

Pan, J., & Ho, M. (2021). Role of glypican-1 in regulating multiple cellular signaling pathways. American Journal of Physiology-Cell Physiology, 321(5), C846-C858.

Munekage, E., Serada, S., Tsujii, S., Yokota, K., Kiuchi, K., Tominaga, K., ... & Naka, T. (2021). A glypican-1-targeted antibody-drug conjugate exhibits potent tumor growth inhibition in glypican-1-positive pancreatic cancer and esophageal squamous cell carcinoma. Neoplasia, 23(9), 939-950.

Lund, M. E., Campbell, D. H., & Walsh, B. J. (2020). The role of glypican-1 in the tumour microenvironment. Tumor Microenvironment: Extracellular Matrix Components–Part A, 163-176.

Nishigaki, T., Takahashi, T., Serada, S., Fujimoto, M., Ohkawara, T., Hara, H., ... & Naka, T. (2020). Anti-glypican-1 antibody–drug conjugate is a potential therapy against pancreatic cancer. British journal of cancer, 122(9), 1333-1341.

Wang, S., Qiu, Y., & Bai, B. (2019). The expression, regulation, and biomarker potential of glypican-1 in cancer. Frontiers in oncology, 9, 614.

Zhou, C. Y., Dong, Y. P., Sun, X., Sui, X., Zhu, H., Zhao, Y. Q., ... & Han, S. X. (2018). High levels of serum glypican‐1 indicate poor prognosis in pancreatic ductal adenocarcinoma. Cancer Medicine, 7(11), 5525-5533.

Frampton, A. E., Prado, M. M., López-Jiménez, E., Fajardo-Puerta, A. B., Jawad, Z. A., Lawton, P., ... & Jiao, L. R. (2018). Glypican-1 is enriched in circulating-exosomes in pancreatic cancer and correlates with tumor burden. Oncotarget, 9(27), 19006.

Matsuzaki, S., Serada, S., Hiramatsu, K., Nojima, S., Matsuzaki, S., Ueda, Y., ... & Naka, T. (2018). Anti‐glypican‐1 antibody‐drug conjugate exhibits potent preclinical antitumor activity against glypican‐1 positive uterine cervical cancer. International journal of cancer, 142(5), 1056-1066.

Campbell, D. H., Lund, M. E., Nocon, A. L., Cozzi, P. J., Frydenberg, M., De Souza, P., ... & Walsh, B. J. (2018). Detection of glypican-1 (GPC-1) expression in urine cell sediments in prostate cancer. PLoS One, 13(4), e0196017.

Huang, X., Fan, C., Zhu, H., Le, W., Cui, S., Chen, X., ... & Chen, B. (2018). Glypican-1-antibody-conjugated Gd–Au nanoclusters for FI/MRI dual-modal targeted detection of pancreatic cancer. International Journal of Nanomedicine, 13, 2585.

Ask a question We look forward to hearing from you.
0 reviews or Q&As
Loading...
Have you used Mouse Anti-GPC1 Recombinant Antibody (CBLG1-1590)?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon $30 eGift Card
Submit a review
Loading...
For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Online Inquiry

Documents

Contact us

  • Tel: (USA)
  • (UK)
  • Fax:
  • Email:

Submit A Review

Go to
Compare